Option chain shows key data for Immunovant's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Immunovant.

Immunovant (NASDAQ:IMVT) Stock, Option Chain

Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

News

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

FULC

ILMN

IMVT

KRYS

Shares of Immunovant (NASDAQ: IMVT) are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves&#39; Disease.

IMVT Stock Up on Upbeat Data From Graves&#39; Disease Study of Batoclimab

ROIV

Health Care

Movers

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves&#39; Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the end of 2024.

What&#39;s Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Titoli a dividendo scelti dai migliori analisti di Wall Street

Short Ideas

Pre-Market Outlook

TERN

Top 2 Health Care Stocks That May Collapse This Quarter

Immunovant Inc

Press Releases

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

Immunovant to Host Graves' Disease Program Update on September 9, 2024

Immunovant Provides Update on Graves' Disease Development Program

Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Immunovant Announces $450 Million Private Placement

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Biohaven

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Amicus Therapeutics

Krystal Biotech

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

PTC Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

TG Therapeutics

Vericel

Veracyte

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

Guggenheim

HC Wainwright & Co.

B of A Securities

Wells Fargo

Raymond James

Comments

Immunovant

Immunovant (IMVT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga